Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST
China has always been believed to be the land of promise for multinational pharmaceutical companies. However, up until recently many organisations have struggled to see a return on their investments. That may all be set to change though.
The country’s recent 2020 healthcare reforms aim to rapidly increase the pace of new drug approvals and fast track innovative treatments, opening up a whole new world of opportunities for the pharmaceutical industry.
Register now for our next live webinar in which emerging markets experts Marc Yates and Helen Ansell will explore China’s evolving healthcare environment, highlight the key changes affecting pharma and show you how to build the market understanding required to launch a brand effectively in this exciting region.
When: Tuesday 16th April 2019
Time: 10:00 EST/ 15:00 GMT / 16:00 CEST
Register now to secure your place »
China’s key growth factors:
Fast track approvals: So far, over 180 foreign pharma products have been granted priority review and will likely hit the market within the next few years.
From an ability to pay to willingness to pay: By 2022 more than half of the urban population will be defined as upper middle class and as incomes rise so does willingness to pay for quality healthcare.
Shifting disease patterns: Diseases of affluence are also on the rise and the benefits of urban life have resulted in an aging population and an explosion in age-related conditions.
What are the key takeaways in this webinar?
1. China 101
An overview of the healthcare environment in China
2. What’s changed?
The key opportunities under China’s 2020 healthcare reform
3. Where to play? How to win?
Design an effective marketing strategy with insights that prepare you for optimal success.
4. Gain answers to your key questions
Start the conversation by submitting your questions in advance when you register.
Register now to secure your place »
If you are unable to attend but would like to view the recording, register now and we will send you a unique link to download it as soon as it is ready.
This content was provided by Inizio
Latest Content from Inizio
Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.
As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...
Discover how our DataGateway platform unifies fragmented real-world oncology data into a single, validated dataset that delivers deeper insights and faster decision-making.
Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.
Discover key insights from ESMO 2025 on how design, emotion, and sustainability are reshaping medical congress experiences. Featuring expert takes from Inizio leaders.
As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...
At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless...
Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.
At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the...
Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.
